Ligand Pharmaceuticals Incorporated
LGND
$104.62
-$2.18-2.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 42.81M | 51.81M | 41.53M | 30.98M | 28.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.81M | 51.81M | 41.53M | 30.98M | 28.10M |
| Cost of Revenue | 7.26M | 8.12M | 8.26M | 8.85M | 7.13M |
| Gross Profit | 35.55M | 43.69M | 33.27M | 22.13M | 20.97M |
| SG&A Expenses | 25.61M | 24.48M | 17.62M | 10.95M | 15.99M |
| Depreciation & Amortization | 8.26M | 8.26M | 8.26M | 8.19M | 8.34M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.13M | 40.86M | 34.14M | 27.99M | 31.46M |
| Operating Income | 1.69M | 10.96M | 7.39M | 2.99M | -3.36M |
| Income Before Tax | -39.20M | -6.34M | -65.39M | 113.45M | 17.10M |
| Income Tax Expenses | -8.11M | 833.00K | -13.48M | 27.31M | -1.09M |
| Earnings from Continuing Operations | -31.09M | -7.17M | -51.91M | 86.14M | 18.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.09M | -7.17M | -51.91M | 86.14M | 18.19M |
| EBIT | 1.69M | 10.96M | 7.39M | 2.99M | -3.36M |
| EBITDA | 10.31M | 19.95M | 16.24M | 11.75M | 5.56M |
| EPS Basic | -1.64 | -0.39 | -2.88 | 4.86 | 1.04 |
| Normalized Basic EPS | 0.48 | -0.30 | -0.85 | 0.09 | 0.07 |
| EPS Diluted | -1.64 | -0.39 | -2.88 | 4.75 | 1.03 |
| Normalized Diluted EPS | 0.48 | -0.30 | -0.85 | 0.09 | 0.07 |
| Average Basic Shares Outstanding | 18.97M | 18.42M | 18.03M | 17.73M | 17.47M |
| Average Diluted Shares Outstanding | 18.97M | 18.42M | 18.03M | 18.12M | 17.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |